nach oben

Erschienen in:

16.03.2024 | Original Research

Postoperative Bisphosphonates Use is Associated with Reduced Adverse Outcomes After Primary Total Joint Arthroplasty of Hip and Knee: A Nationwide Population-Based Cohort Study

verfasst von: Jen-Ta Shih, Timothy L. Tan, Pei-Hung Shen, Tsu-Te Yeh, Chia-Chun Wu, Ru-Yu Pan, Wu-Chien Chien, Chi-Hsiang Chung, Sheng-Hao Wang

Erschienen in: Calcified Tissue International | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Bisphosphonates have been associated with a decreased risk of revision surgery after total joint arthroplasty of the hip or knee (TJA) because of their effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent, and the influence of bisphosphonates on associated complications and subsequent TJA remains unknown. This study investigated the association between the use of bisphosphonates and the risk of adverse outcomes after primary TJA. This matched cohort study utilized the National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000–December 2015 inclusive). Study participants were further categorized into two groups, bisphosphonate users and nonusers, using propensity score matching. The Kaplan–Meier curve analysis and adjusted hazard ratios (aHRs) of revision surgery, adverse outcomes of primary surgery and subsequent TJA were calculated using Cox regression analysis. This study analyzed data from 6485 patients who underwent total hip arthroplasty (THA) and 20,920 patients who underwent total knee arthroplasty (TKA). The risk of revision hip and knee arthroplasty was significantly lower in the bisphosphonate users than in the nonusers (aHR, 0.54 and 0.53, respectively). Furthermore, the risk of a subsequent total joint arthroplasty, adverse events and all-cause mortality were also significantly reduced in the bisphosphonate users. This study, involving a large cohort of patients who underwent primary arthroplasties, revealed that bisphosphonate treatment may potentially reduce the risk of revision surgery and associated adverse outcomes. Furthermore, the use of bisphosphonates after TJA is also associated with a reduced need for subsequent arthroplasty.

Research Registration Unique Identifying Number (UIN): ClinicalTrials.gov Identifier—NCT05623540 (https://clinicaltrials.gov/show/NCT05623540).

Nur mit Berechtigung zugänglich

Chen A, Gupte C, Akhtar K, Smith P, Cobb J (2012) The global economic cost of osteoarthritis: how the UK compares. Arthritis 2012:698709. https://doi.org/10.1155/2012/698709CrossRefPubMedPubMedCentral

Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380(9859):2163–2196. https://doi.org/10.1016/s0140-6736(12)61729-2CrossRefPubMedPubMedCentral

Murray CJL (2013) The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA 310(6):591. https://doi.org/10.1001/jama.2013.13805CrossRefPubMed

Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M et al (2014) The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1323–1330. https://doi.org/10.1136/annrheumdis-2013-204763CrossRefPubMed

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N et al (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16(2):137–162. https://doi.org/10.1016/j.joca.2007.12.013CrossRefPubMed

Harris WH, Sledge CB (1990) Total hip and total knee replacement (1). N Engl J Med 323(11):725–731. https://doi.org/10.1056/NEJM199009133231106CrossRefPubMed

Murphy LB, Helmick CG, Schwartz TA, Renner JB, Tudor G, Koch GG et al (2010) One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage 18(11):1372–1379. https://doi.org/10.1016/j.joca.2010.08.005CrossRefPubMedPubMedCentral

Losina E, Thornhill TS, Rome BN, Wright J, Katz JN (2012) The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am 94(3):201–207. https://doi.org/10.2106/JBJS.J.01958CrossRefPubMedPubMedCentral

Kurtz S, Ong K, Lau E, Mowat F, Halpern M (2007) Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89(4):780–785. https://doi.org/10.2106/JBJS.F.00222CrossRefPubMed

10.

Patel A, Pavlou G, Mújica-Mota RE, Toms AD (2015) The epidemiology of revision total knee and hip arthroplasty in England and Wales: a comparative analysis with projections for the United States. A study using the National Joint Registry dataset. Bone Joint J. 97-B(8):1076–81. https://doi.org/10.1302/0301-620x.97b8.35170CrossRefPubMed

11.

Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Lie SA, Vollset SE (2000) The Norwegian arthroplasty register: 11 years and 73,000 arthroplasties. Acta Orthop Scand 71(4):337–353. https://doi.org/10.1080/000164700317393321CrossRefPubMed

12.

Vasso M, Beaufils P, Cerciello S, Schiavone PA (2014) Bone loss following knee arthroplasty: potential treatment options. Arch Orthop Trauma Surg 134(4):543–553. https://doi.org/10.1007/s00402-014-1941-8CrossRefPubMed

13.

Abu-Amer Y, Darwech I, Clohisy JC (2007) Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 9(Suppl 1):S6. https://doi.org/10.1186/ar2170CrossRefPubMedPubMedCentral

14.

Russell RGG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19. https://doi.org/10.1016/j.bone.2011.04.022CrossRefPubMed

15.

Shanbhag AS (2006) Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg 14(4):215–225. https://doi.org/10.5435/00124635-200604000-00003CrossRefPubMed

16.

Hilding M, Aspenberg P (2007) Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. Acta Orthop 78(6):795–799. https://doi.org/10.1080/17453670710014572CrossRefPubMed

17.

Hilding M, Aspenberg P (2006) Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthop 77(6):912–916. https://doi.org/10.1080/17453670610013213CrossRefPubMed

18.

Thillemann TM, Pedersen AB, Mehnert F, Johnsen SP, Søballe K (2010) Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone 46(4):946–951. https://doi.org/10.1016/j.bone.2010.01.377CrossRefPubMed

19.

Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C et al (2011) Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ 343:d7222. https://doi.org/10.1136/bmj.d7222CrossRefPubMedPubMedCentral

20.

Teng S, Yi C, Krettek C, Jagodzinski M (2015) Bisphosphonate use and risk of implant revision after total hip/knee arthroplasty: a meta-analysis of observational studies. PLoS ONE 10(10):e0139927. https://doi.org/10.1371/journal.pone.0139927CrossRefPubMedPubMedCentral

21.

Hansson U, Toksvig-Larsen S, Ryd L, Aspenberg P (2009) Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: a double-blind randomized RSA study. Acta Orthop 80(1):41–45. https://doi.org/10.1080/17453670902804968CrossRefPubMedPubMedCentral

22.

Walsh DA, Chapman V (2011) Bisphosphonates for osteoarthritis. Arthritis Res Ther 13(5):128. https://doi.org/10.1186/ar3448CrossRefPubMedPubMedCentral

23.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al (2014) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12(12):1495–1499. https://doi.org/10.1016/j.ijsu.2014.07.013CrossRef

24.

Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P et al (2014) Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort: bisphosphonate use and implant survival. Arthritis Rheumatol 66(11):3233–3240. https://doi.org/10.1002/art.38789CrossRefPubMed

25.

Kozma C, Dickson Phillips, Meletiche. (2013) Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. https://doi.org/10.2147/ppa.s40736CrossRefPubMedPubMedCentral

26.

Fu S-H, Wang C-Y, Yang R-S, Wu F-LL, Hsiao F-Y (2017) Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan. J Bone Joint Surg Am. 99(11):938–46. https://doi.org/10.2106/JBJS.16.00385CrossRefPubMed

27.

Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619. https://doi.org/10.1016/0895-4356(92)90133-8CrossRefPubMed

28.

National Joint Registry. National Joint Registry for England and Wales. 2009

29.

Paling IH (2000) Wear in total hip and knee replacements. J Bone Joint Surg-Am Volume 82(12):1806. https://doi.org/10.2106/00004623-200012000-00020CrossRef

30.

Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D et al (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 50(11):3516–3525. https://doi.org/10.1002/art.20627CrossRefPubMed

31.

Vaysbrot EE, Osani MC, Musetti M-C, McAlindon TE, Bannuru RR (2018) Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 26(2):154–164. https://doi.org/10.1016/j.joca.2017.11.013CrossRefPubMed

32.

Kiyomoto K, Iba K, Hanaka M, Ibe K, Hayakawa H, Teramoto A et al (2020) High bone turnover state under osteoporotic changes induces pain-like behaviors in mild osteoarthritis model mice. J Bone Miner Metab 38(6):806–818. https://doi.org/10.1007/s00774-020-01124-yCrossRefPubMed

33.

Fernández-Martín S, López-Peña M, Muñoz F, Permuy M, González-Cantalapiedra A (2021) Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020. Arthritis Res Ther 23(1):60. https://doi.org/10.1186/s13075-021-02446-6CrossRefPubMedPubMedCentral

34.

Tande AJ, Patel R (2014) Prosthetic joint infection. Clin Microbiol Rev 27(2):302–345. https://doi.org/10.1128/CMR.00111-13CrossRefPubMedPubMedCentral

35.

Verdrengh M, Carlsten H, Ohlsson C, Tarkowski A (2007) Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis. J Orthop Res 25(3):304–310. https://doi.org/10.1002/jor.20317CrossRefPubMed

36.

Hiltunen AK, Vuorela PM (2014) Fallarero bisphosphonates offer protection against prosthetic joint infections caused by Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Drug Deliv Sci Technol 27:302–345. https://doi.org/10.1128/CMR.00111-13CrossRef

37.

Benkovich V, Klassov Y, Mazilis B, Bloom S (2020) Periprosthetic fractures of the knee: a comprehensive review. Eur J Orthop Surg Traumatol 30(3):387–399. https://doi.org/10.1007/s00590-019-02582-5CrossRefPubMed

38.

Ramavath A, Lamb JN, Palan J, Pandit HG, Jain S (2020) Postoperative periprosthetic femoral fracture around total hip replacements: current concepts and clinical outcomes. EFORT Open Rev 5(9):558–567. https://doi.org/10.1302/2058-5241.5.200003CrossRefPubMedPubMedCentral

39.

MacKenzie SA, Ng RT, Snowden G, Powell-Bowns MFR, Duckworth AD, Scott CEH (2019) Periprosthetic atypical femoral fractures exist and are associated with duration of bisphosphonate therapy. Bone Joint J 101(10):1285–91. https://doi.org/10.1302/0301-620X.101B10.BJJ-2019-0599.R2CrossRefPubMed

40.

Ben-Shlomo Y, Blom A, Boulton C, Brittain R, Clark E, Craig R, et al. The National Joint Registry 16th Annual Report 2019. https://pubmed.ncbi.nlm.nih.gov/32744812/

41.

Nasser AAH, Chauhan G, Osman K, Nandra S, Nandra R, Mahmood A (2021) Study protocol for a national retrospective review of femoral periprosthetic fracture management. Is there variation in practice? J Surg Protoc Res Methodol. https://doi.org/10.1093/jsprm/snab004CrossRef

42.

Tai TW, Huang CF, Huang HK, Yang RS, Chen JF, Cheng TT et al (2023) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update. J Formos Med Assoc. https://doi.org/10.1016/j.jfma.2023.01.007CrossRefPubMedPubMedCentral

43.

Holzer LA, Borotschnig L, Holzer G (2023) Evaluation of FRAX in patients with periprosthetic fractures following primary total hip and knee arthroplasty. Sci Rep 13(1):7145. https://doi.org/10.1038/s41598-023-34230-8CrossRefPubMedPubMedCentral

44.

Dózsai D, Ecseri T, Csonka I, Gárgyán I, Doró P, Csonka Á (2020) Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy. J Orthop Surg Res 15(1):414. https://doi.org/10.1186/s13018-020-01941-xCrossRefPubMedPubMedCentral

45.

Ro C, Cooper O (2013) Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep 11(1):45–51. https://doi.org/10.1007/s11914-012-0129-9CrossRefPubMedPubMedCentral

46.

Hooper GJ, Rothwell AG, Stringer M, Frampton C (2009) Revision following cemented and uncemented primary total hip replacement. J Bone Joint Surg Br Volume 91-B(4):451–8. https://doi.org/10.1302/0301-620X.91B4.21363CrossRef

47.

Okike K, Chan PH, Prentice HA, Paxton EW, Burri RA (2020) Association between uncemented vs cemented hemiarthroplasty and revision surgery among patients with hip fracture. JAMA 323(11):1077. https://doi.org/10.1001/jama.2020.1067CrossRefPubMedPubMedCentral

48.

Konan S, Abdel MP, Haddad FS (2019) Cemented versus uncemented hip implant fixation. Bone Joint Res 8(12):604–607. https://doi.org/10.1302/2046-3758.812.BJR-2019-0337CrossRefPubMed

Titel: Postoperative Bisphosphonates Use is Associated with Reduced Adverse Outcomes After Primary Total Joint Arthroplasty of Hip and Knee: A Nationwide Population-Based Cohort Study
verfasst von: Jen-Ta Shih
Timothy L. Tan
Pei-Hung Shen
Tsu-Te Yeh
Chia-Chun Wu
Ru-Yu Pan
Wu-Chien Chien
Chi-Hsiang Chung
Sheng-Hao Wang
Publikationsdatum: 16.03.2024
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 5/2024
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-024-01192-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Osteosarcopenia: Adjust for the BMI or Bare the Bias

The Impact of Non-alcohol Fatty Liver Disease on Bone Mineral Density is Mediated by Sclerostin by Mendelian Randomization Study

Roles of Plasminogen Activator Inhibitor-1 in Heterotopic Ossification Induced by Achilles Tenotomy in Thermal Injured Mice

Correction to: BMP2 Modified by the m6A Demethylation Enzyme ALKBH5 in the Ossification of the Ligamentum Flavum Through the AKT Signaling Pathway

Opportunistic Identification of Vertebral Compression Fractures on CT Scans of the Chest and Abdomen, Using an AI Algorithm, in a Real-Life Setting